Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Open accessThe DOI matches its Crossref record; 155 of the 158 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-β, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It modulates glutamate transmission and dopamine receptors, exhibiting certain efficacy in improving patients’ cognitive function, daily living abilities, and behavior.409,410”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [410]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Donepezil, galantamine, and rivastigmine are the cholinesterase inhibitors that are most frequently prescribed [102,103,104,105,106].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This study showed a dose-time-dependent reduction in Aβ plaques and an improvement in clinical manifestations of AD, as assessed by the Clinical Dementia RatingSum of Boxes (CDR-SB) and Mini Mental State Examination (MMSE) scores for the highest dose [20].”
MethodCraft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · cited 1×
“For example, a phase 3 clinical trial showed that Semagacestat (LY-450139) did not improve cognitive abilities and, in the case of patients receiving a higher dose, caused a worsening of functional capacity, as well as an increased risk of skin cancer and infections [77].”
BackgroundMcShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 2×
“However, despite the good results obtained in in vivo studies, no improvement in cognitive status, and no reduction of tau in the CSF of patients under treatment was observed [104,105].”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“A phase 2 study involving individuals with prodromal AD, and a phase 3 clinical trial studying the efficacy of this treatment at disease onset are currently underway [100,101].”
BackgroundBeneficial effects of physical exercise on neuroplasticity and cognition
Hötting, K., & Röder, B. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.04.005 · Cited by 991
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · cited 3×
“In one phase 3 clinical trial, participants with mild and moderate AD showed good tolerability, but no decrease in cognitive and functional impairment [75].”
BackgroundInfluential
Research works printed but not linked: 3
- Biogen Highlights of Prescribing Information: Aduhelmtm (Aducanumab-Avwa) Injection, for Intravenous Use Initial U.S. Approval: 2021 Biogen Cambridge, MA, USA 2021
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2022 29763201
- Buchanan T. De Bruyn S. Fadini T. Watanabe S. Germani M. Mesa A.B.I.R. A Randomised, Placebo-Controlled, First-in-Human Study with a Central Tau Epitope Antibody–UCB0107 Proceedings of the International Congress of Parkinson’s Disease and Movement Disorders Nice, France 22–26 September 2019
Cited by
Items 201–237 of 237
Sarwad, A., Housgoudar, S., -, S. B., Patil, V., Akki, A. J., & Parvatikar, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34059-8.00006-3
Orooji, N., Ahmadi, F., Javadivala, Z., Mahdavi, A. M., & Jafarpour, M. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2635989
Maladaptive aging trajectory in late-onset Alzheimer's disease
Lv, T., Sun, H., Xia, T., Zhu, M. L., & Li, Y. (2026) · The Innovation Life · doi:10.59717/j.xinn-life.2026.100206
Hao, X., Gao, W., & Lu, Y. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-111183
Hussain, M., Ikram, M., & Vohora, D. (2026) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70079
Lactobacillus paragasseri ameliorates age-dependent thermotaxis decline in Caenorhabditis elegans
Tanaka, M., Tsukada, S., Jang, M., Aleogho, B. M., Mori, I., & Noma, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-48002-7 · Cited by 2
Green carbon dots in neurological disorders
Thokchom, B., Singh, S. R., Bhavi, S. M., Abbigeri, M. B., Kulkarni, S. R., Padti, A. C., & Yarajarla, R. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34121-2.00011-x
Case Studies and Patents in Alzheimer’s Disease Research
Kumar, D., Anand, P., Tiwari, J., & Singh, S. N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010016
Recent Advances in Drug Development for the Management of Alzheimer’s Disease
Upadhyay, A., Singh, A. K., Jayaswal, N., Jaiswal, P., Singh, S. N., & Tewari, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010014
Chang, W., Chen, Y., Kan, J., Huang, X., & Luo, K. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71702
Schuller, A. J., Hager, M. R., Briggs, A. M., Rocha, S. M., Yanouri, O. A., Smith, E. J., Hall, S. E., Montrose, L. B., & Tjalkens, R. B. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1805957
Green Coffee Bean Extract Mitigates Alzheimer’s Disease in Male Rats
Abu-Almakarem, A. S., Alzahrani, O. R., Abu‐Khudir, R., Alassar, S. R., El-Said, K. S., Alkhodair, S. A., Banjabi, A. A., Al-Bazi, M. M., Mobasher, M. A., & Soliman, M. M. (2026) · Journal of Food Biochemistry · doi:10.1155/jfbc/5511502
Antibody-Based Medicines Versus Conventional Treatments for Alzheimer’s Disease
Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_13
Pan, J., & Kelley, G. A. (2026) · Applied Sciences · doi:10.3390/app16115395
Sharma, D. K., & Prasad, C. S. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2683967
A review on thymoquinone: a promising therapeutic molecule in Alzheimer's
Kaur, S. D., SINGH, V. A., Kaurav, H., Nangare, S., & Vihal, S. (2026) · Nutritional Neuroscience · doi:10.1080/1028415x.2026.2682949
Wang, X., Zhang, W., He, J., Zhang, X., Wang, R., & Li, Z. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261458818 · Cited by 1
Hu, H., Xiong, G., Liu, F., Peng, J., Lin, Y., Chen, C., Zuo, Y., Chen, G., Liao, X., Cao, Z., et al. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106207
Gohar, N., Abbas, M., Masaud, S. M., Zulfiqar, I., Jabeen, H., Malik, N. S., & Nadeem, H. (2026) · ACS Omega · doi:10.1021/acsomega.6c01108
Tau Protein in Alzheimer's Disease
Mukherjee, M., Dhara, S., Jana, A., & Roy, T. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010005
Pal, T., Mukherjee, S., Karati, D., Pahari, N., Hossain, C. M., & Naskar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010017
Kiser, H., Budu‐Aggrey, A., Bailey, J. N. C., Villaplana-Velasco, A., Bernabéu, M. O., Jiang, X., Owen, C. G., Haines, J. L., Pasquale, L. R., MacGregor, S., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100635
Sheikh, S., Mollah, F., Chowdhury, R., Oni, M. I. J., Khatun, M. M., Shadin, M., Bhuia, M. S., Hoque, M. A., Alfaifi, M., Altemani, F. H., et al. (2026) · ChemistrySelect · doi:10.1002/slct.73819
Dhiwar, P. S., Das, P. K., Panda, S., Prasad, P., Zambre, V. P., & Zanchi, F. B. (2026) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025603726
Curcumin-Based Nanocarriers for Alzheimer’s Disease: A Promising Therapeutic Avenue
Jayalath, W. T., Gunaratna, M. J., Kadigamuwa, C. C., Thambiliyagodage, C. J., & Dahanayake, J. N. (2026) · Applied Biosciences · doi:10.3390/applbiosci5030069
Computational insights into the anti-Alzheimer potential of alkynyl-3-carboxamide derivatives
Noor, A. I., Suha, H. N., Hossain, I., Almatarneh, M. H., Al-Msiedeen, A. M. H., Bari, M. A. U., Poirier, R. A., & Uddin, K. M. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d6cp00485g
Ohara, K., Zhang, H., Shibata, H., & Hasegawa, Y. (2026) · Journal of Dietary Supplements · doi:10.1080/19390211.2026.2718077
The role of acupuncture in the dendritic cell vaccine against Alzheimer's disease
Hong, Y., Shen, N., Yang, H., Ahmed, G., Regmi, D., Lin, X., Guo, N., Hearn, G., Sawmiller, D. R., & Cao, C. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261490135
The role of AI in neuroethics and patients’ privacy
Nagpal, D., Madaan, V., Agrawal, P., & Mittal, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27722-1.00006-7
Nose-to-Brain Inorganic Nanosystems for Alzheimer’s Disease Theranostics
González-Pizarro, C., Vitta, Y., & Kogan, M. J. (2026) · Journal of Pharmaceutical and BioTech Industry · doi:10.3390/jpbi3040024
Kumar, A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02417-w
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
BindingDB Entry 50019599: First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT
BindingDB (2024) · UC San Diego · doi:10.7270/q2n302bv
BindingDB Entry 50021197: Selenization of Small Molecule Drugs: A New Player on the Board.
BindingDB (2025) · UC San Diego · doi:10.7270/q2m331cq
Metadata
- Authors
- Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L.
- Affiliations
- Instituto Nacional de Gestión Sanitaria (INGESA), Primary Health Care, 51003 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences (Melilla), University of Granada, 52005 Granada, Spain
- Universidad de Sevilla (ES)
- Department of Biomedicine, Biotechnology and Public Health, Physiology Area, Faculty of Medicine, University of Cádiz, Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Biomedicine, Biotechnology and Public Health, Immunology Area, University of Cádiz Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Physiology, Faculty of Health Sciences (Ceuta), University of Granada, 51001 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-05-24
- Volume
- 14
- Issue
- 6
- Pages
- 1117
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9228613
- OpenAlex
- W4281488754
- Cited by
- 239
- References
- 158
- Citations by year
- 2026: 52 · 2025: 62 · 2024: 66 · 2023: 48 · 2022: 11
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- RODIN (Universidad de Cádiz) (submittedVersion, cc-by)
- Funders
- Junta de Andalucía, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- the Ministry of Science and Innovation, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, amyloid-beta, tau hyperphosphorylation, amyloid plaques, neurofibrillary tangles, aducanumab, donepezil, galantamine, rivastigmine, memantine, gamma-secretase inhibitors, beta-secretase inhibitors, aggregation inhibitors, amyloid-beta clearance, tau aggregation inhibitors, dementia treatment, lifestyle intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.